OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Samuelson on the Comorbidities that Affect Treatment Decisions in Prostate Cancer

August 8th 2018

Scott Samuelson, MD, medical oncologist at Utah Cancer Specialists, discusses the comorbidities that may affect treatment decisions for patients with metastatic prostate cancer.

Dr. Grivas on the IMvigor211 Trial in Metastatic Urothelial Carcinoma

August 8th 2018

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the IMvigor211 trial in metastatic urothelial carcinoma.

Dr. Borgen Discusses Axillary Node Dissection in Early-Stage Breast Cancer

August 7th 2018

Patrick I. Borgen, MD, chairman of surgery, director of the Breast Cancer Program, Maimonides Medical Center, discusses axillary node dissection in patients with early-stage breast cancer.

Dr. Finn Discusses Sequencing Therapy for HCC

August 7th 2018

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, discusses sequencing therapy for patients with hepatocellular carcinoma.

Dr. Drake on the Role of Cytoreductive Nephrectomy in RCC

August 7th 2018

Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the role of cytoreductive nephrectomy in the treatment of patients with renal cell carcinoma.

Dr. Hurvitz on the Impact of Biosimilars

August 7th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the impact of biosimilars in the treatment of patients with breast cancer.

Dr. Bailey Discusses the Treatment of Pediatric Patients With Sarcoma

August 7th 2018

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses the treatment of pediatric patients with sarcoma.

Dr. Bekaii-Saab Reflects on the Findings of the ReDOS Trial in mCRC

August 7th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, reflects on the findings from the ReDOS study in patients with metastatic colorectal cancer.

Dr. Ansell on Strategies to Address Immune Evasion in Lymphoma

August 7th 2018

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses strategies addressing immune evasion in patients with lymphoma.

Dr. Ellis on the Entrance of Biosimilars Into the Field of Oncology

August 6th 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the entrance of biosimilars into the field of oncology.

Dr. O'Brien on Sequencing Small Molecule Inhibitors in CLL

August 6th 2018

Susan M. O’Brien, MD, hematologist/oncologist at University of California, Irvine Health, discusses sequencing small molecule inhibitors in chronic lymphocytic leukemia (CLL).

Dr. Murthy on Dual HER2 Blockade in HER2+ Breast Cancer

August 6th 2018

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses dual HER2 blockade in HER2-positive breast cancer.

Dr. Kurtz Discusses Using ctDNA to Detect Lymphoma

August 3rd 2018

David M. Kurtz, MD, PhD, instructor of medicine, Postdoctoral Fellow, Divisions of Oncology & Hematology, Stanford Cancer Center, Stanford University, discusses using circulating tumor DNA to detect lymphoma.

Dr. Maloney on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

August 3rd 2018

David G. Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the promise of CAR T-cell therapy in hematologic malignancies.

Dr. Galsky on Neoadjuvant Immune Checkpoint Blockade in Bladder Cancer

August 3rd 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses neoadjuvant immune checkpoint inhibition in patients with bladder cancer.

Dr. Langer on the Impact of Frontline Immunotherapy in Lung Cancer

August 3rd 2018

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of frontline immunotherapy in lung cancer.

Dr. Konecny on Response to PARP Inhibitors in Ovarian Cancer

August 3rd 2018

Gottfried E. Konecny, MD, associate professor of medicine, University of California, Los Angeles, discusses response to PARP inhibitors in ovarian cancer.

Dr. Agarwal on Emerging Immunotherapeutic Combinations in Kidney Cancer

August 3rd 2018

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses emerging immunotherapeutic combinations in kidney cancer.

Dr. Goy on the Combination of Biological Therapies in Relapsed MCL

August 3rd 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the combination of biological therapies in the treatment of patients with relapsed mantle cell lymphoma (MCL).

Dr. Herbst on TMB as a Biomarker in NSCLC

August 3rd 2018

Roy S. Herbst, MD, PhD, professor of medicine, chief of medical oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses tumor mutational burden (TMB) as a biomarker in non–small cell lung cancer (NSCLC).